UK markets close in 6 hours 39 minutes

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
25.80-0.46 (-1.75%)
At close: 04:00PM EDT
26.56 +0.76 (+2.95%)
Pre-market: 04:07AM EDT

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887

IndustryDiagnostics & Research
Full-time employees1,793

Key executives

NameTitlePayExercisedYear born
Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman11.63kN/A1979
Dr. AmirAli Talasaz Ph.D.Co-CEO & Director11.18kN/A1979
Mr. Michael BellChief Financial Officer630.99kN/A1969
Mr. John G. SaiaChief Legal Officer & Corp. Sec.627.18kN/A1973
Dr. Craig Eagle M.D.Chief Medical Officer649.13kN/A1967
Mr. Christopher FreemanChief Commercial Officer630.39kN/A1974
Ms. Ines Dahne-SteuberChief Operating OfficerN/AN/AN/A
Ms. Darya ChudovaChief Technology OfficerN/AN/AN/A
Mr. Kumud KaliaChief Information OfficerN/AN/A1966
Ms. Jennifer HigginsVP of Public AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Corporate governance

Guardant Health, Inc.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.